Baylor Scott & White Charles A. Sammons Cancer Center | Strategic Alliance Partners

Baylor Research Institute (BRI) at Dallas and the Translational Genomics Research Institute in Phoenix, AZ, today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.

Daniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

M. Yair Levy, MD, discussed the impact of non-chemotherapeutic agents on the treatment of patients with NHL in an interview with OncLive.

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.

In an interview with OncLive, James W. Fleshman Jr, MD, explained how technological advances and a growing commitment to a multidisciplinary approach have impacted the treatment of colorectal cancer.

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System, discusses immunotherapy for cancer treatment.

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

A subgroup analysis from a phase III study showed that certain patients may benefit more from eribulin than capecitabine, and quality of life data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

Joyce A. O'Shaughnessy, MD, from the Baylor Charles A. Sammons Cancer Center, reviews findings from Study 301, which compared eribulin mesylate to capecitabine for patients with locally advanced or metastatic breast cancer.